Diseases & Conditions Market Research Reports & Industry Analysis
Insomnia is a common condition in which one has trouble going to sleep or staying asleep. This condition can range from weak to strong, depending on how often it occurs and for how long. Insomnia can be ongoing or acute. Chronic insomnia means having symptoms at least 3 nights a week for more than a month. Acute insomnia lasts for less time. Some people who have insomnia will have trouble falling asleep. Other people may fall asleep easily but, then wake up.
Diseases & Conditions Industry Research & Market Reports
-
Global & Colombia Cancer Therapeutics Market to 2031
... including chemotherapy and targeted therapies, to manage various cancer types such as breast cancer. In response, the Colombian government has implemented several measures to enhance cancer care and improve patient access to therapies. The National ... Read More
-
Global & Chile Cancer Therapeutics Market to 2031
... and Social Affairs reported that in 2019, around 11.5% of Chile's population was aged 65 or older, and this figure is projected to rise to 21% by 2041. Chile’s public health insurer, FONASA, currently provides ... Read More
-
Global & Algeria Cancer Therapeutics Market to 2031
... to treatment and improve patient outcomes by strengthening its healthcare infrastructure and introducing more advanced therapies. Acknowledging the urgency of addressing this public health challenge, the Algerian government—through the Ministry of Health—has implemented several measures ... Read More
-
Global & New Zealand Cancer Therapeutics Market to 2031
... and death, with lung, breast, prostate, and colorectal cancers being the most prevalent. The incidence of cancer has steadily grown in recent years, driven by factors such as an aging population, lifestyle changes, and environmental ... Read More
-
Global & Singapore Cancer Therapeutics Market to 2031
... one of the top causes of mortality in the country. As global cancer care evolves, Singapore has emerged as a prominent center for oncology drug development, attracting both domestic and international pharmaceutical companies to conduct ... Read More
-
Global & Oman Cancer Therapeutics Market to 2031
... is an increasing demand for effective treatment options, driving growth in the cancer therapeutics market. Oman’s Ministry of Health (MOH) has been actively working to strengthen the healthcare system, particularly in oncology. Key institutions such ... Read More
-
Global & Nigeria Cancer Therapeutics Market to 2031
... with breast cancer representing the highest proportion at 40.5%. This increasing cancer burden has led to a rising demand for effective cancer treatments, pushing the country’s healthcare system to strengthen its response. The Nigerian government ... Read More
-
Global & Japan Cancer Therapeutics Market to 2031
... least 500,000 individuals in the country are aged 65 or older. Projections from Japan’s National Institute of Population and Social Security Research estimate that by 2050, 37.7% of the population will fall into this age ... Read More
-
Global & Canada Cancer Therapeutics Market to 2031
... breast, prostate, and colorectal cancers. According to the Canadian Cancer Society, an estimated 28,600 women were diagnosed with breast cancer in 2022, accounting for roughly 25% of all new cancer cases among women in Canada. ... Read More
-
Global & Bulgaria Cancer Therapeutics Market to 2031
... million euros, with approximately 69% of patients bearing out-of-pocket costs. Key risk factors such as smoking, poor dietary habits, and alcohol consumption contribute to the high prevalence of cancer in the country, with breast and ... Read More
-
Global & Australia Cancer Therapeutics Market to 2031
... leading cause of cancer-related deaths, particularly affecting First Nations communities, where both smoking and cancer rates remain disproportionately high. Data from the Cancer Australia 2023 report revealed that 14,529 new cases of lung cancer were ... Read More
-
Global & Belgium Cancer Therapeutics Market to 2031
... incidence of cancer is driving increased demand for effective cancer treatments. As more patients seek care, healthcare providers are in need of innovative therapies to address various cancer types. In June 2024, Belgium introduced an ... Read More
-
Global & Slovakia Cancer Therapeutics Market to 2031
... alcohol consumption stands at 10 liters, exceeding the average across the European Union. Cancer screening rates are also below optimal levels; in 2023-2024, only about 25% of the eligible population underwent breast cancer screening, compared ... Read More
-
Global & South Africa Cancer Therapeutics Market to 2031
... component of national expenditure. With both government and private sector investments increasing to enhance healthcare infrastructure, there is a growing demand for therapeutic solutions. As home to one of Africa’s most advanced healthcare systems, South ... Read More
-
Global & Russia Cancer Therapeutics Market to 2031
... saw over 600,000 new cancer cases in 2023, alongside approximately 300,000 cancer-related deaths. The most common cancers include lung, breast, colorectal, and prostate cancers, with lung cancer posing a major challenge due to high smoking ... Read More
-
Global & Peru Cancer Therapeutics Market to 2031
... related deaths were recorded in 2020. The same data also shows that around 4,636 new colorectal cancer cases were diagnosed across all age groups. The rising number of cancer diagnoses is driving demand for effective ... Read More
-
Global & Netherlands Cancer Therapeutics Market to 2031
... enhancing cancer treatment and patient outcomes. In September 2024, the Dutch Research Council (NWO) allocated US$ 27.8 million (25 million euros) to tackle the rising challenges in cancer care. With the number of cancer patients ... Read More
-
Global & Kuwait Cancer Therapeutics Market to 2031
... 20.5% of all diagnosed cancers. The five-year prevalence rate for breast cancer across all age groups stood at 211.30 per 100,000 people. It was also the leading cause of cancer-related deaths among women in Kuwait, ... Read More
-
Global & Indonesia Cancer Therapeutics Market to 2031
... new cancer cases and nearly 300,000 cancer-related deaths. Factors such as a large population base, tobacco use, poor dietary habits, and environmental pollution are key contributors to the increasing incidence of cancer. In response, the ... Read More
-
Global & Denmark Cancer Therapeutics Market to 2031
... out of three individuals have a close family member affected by the disease. Projections indicate that between 2023 and 2050, cancer will account for 30% of all premature deaths (those occurring before age 75), translating ... Read More
-
Global & Bahrain Cancer Therapeutics Market to 2031
... predispositions contribute to the expected increase in cancer incidence in the country. Key risk factors for colorectal cancer include obesity, sedentary behavior, smoking, and diets high in fat but low in fiber, with nearly one-third ... Read More
-
Global & Thailand Cancer Therapeutics Market to 2031
... inhibitors like Keytruda (pembrolizumab) and Opdivo (nivolumab) have become more accessible in Thailand, offering promising options for patients with melanoma, non-small cell lung cancer (NSCLC), bladder cancer, and other cancers. These therapies enhance the immune ... Read More
-
Global & United States Cancer Therapeutics Market to 2031
... reach around 2 million. Colorectal cancer ranks as the third most commonly diagnosed cancer among both men and women in the U.S., according to the American Society of Clinical Oncology. In 2023, about 150,000 adults ... Read More
-
Global & United Kingdom Cancer Therapeutics Market to 2031
... by 2040.The emergence of immune checkpoint inhibitors has significantly transformed cancer treatment, offering renewed hope to patients. The UK also hosts Cancer Research UK, the world’s largest independent cancer charity. Each year, the organization allocates ... Read More
-
Global & United Arab Emirates Cancer Therapeutics Market to 2031
... In the federal budget for 2022, 8.4% of the government’s approved public spending—totaling US$15.8 billion (AED 58.931 billion)—was allocated to the healthcare sector. The UAE government remains the primary financier of its healthcare system and ... Read More
Research Assistance
